The UK’s Medicines and Healthcare products Regulatory Agency is linking hands with its counterpart in India in a move designed to boost public safety in both nations.
News
US green light for Gilead’s PAH combo
The US Food and Administration has cleared a new treatment approach for pulmonary arterial hypertension which combines Gilead’s Letairis and Lilly’s tadalafil to magnify the benefits offered by each therapy alone.
Vernalis snaps up US rights to once-daily antibiotic
UK drugmaker Vernalis has bought US rights to the long-acting antibiotic Moxatag, the first and only approved once-daily formulation of amoxicillin, further strengthening its foothold across the pond.
Merck’s Keytruda picks up US nod for NSCLC
US regulators have widened the scope of Merck & Co’s immunotherapy Keytruda to include the treatment of certain patients with lung cancer.
Teva snaps up Mexican drugmaker for $2.3 bn
Israeli drugmaker Teva is buying Mexican drugmaker Rimsa for $2.3 billion, expanding its presence in one of the world’s top five emerging markets.
Novartis buys into XOMA’s immuno-oncology programme
Novartis has licensed a potential first-in-class immuno-oncology programme from XOMA in a deal potentially worth more than $500 million, sending the latter’s shares up nearly 50%.
Novartis seeks approval for second Amgen biosimilar
The FDA has accepted Novartis’ submission for its biosimilar of Amgen’s Enbrel, which could mark the second time Amgen sees biosimilar competition from the Swiss company.
Berg brings artificial intelligence to 100,000 Genomes Project
Private US biotech Berg is bringing its artificial intelligence technology to the UK’s 100,000 Genomes Project, in order to help analyse massive datasets relating to patients and cell biology.
BMS’ Opdivo/Yervoy combo wins US nod for skin cancer
US regulators have approved the first combination of two immuno-oncology agents – Bristol-Myers Squibb’s Opdivo and Yervoy – to treat certain patients with advanced skin cancer.
Cost of general practice will hit £1.2bn a year by 2025, warns RCGP
General practice will cost the National Health Service £1.2 billion a year by 2025 because of an “explosion” of people living with long-term conditions, the Royal College of General Practitioners has warned.
GPs feel ‘misunderstood’ by pharma, survey shows
A survey of 551 GPs in England has revealed a growing divide between GPs and pharma, with two-thirds no longer meeting with sales representatives and more than 40% having a negative perception of the industry.
GSK delves deeper into inhaled therapeutics with Liquidia deal
GlaxoSmithKline has exercised an option to license inhaled therapeutics created via a particle manipulating technology developed by University of North Carolina spinout Liquidia Technologies, under a pre-existing collaboration between the firms dating back to 2012.
Merck sells Kuvan rights back to BioMarin
Merck Serono has reversed its deal with BioMarin for the rights to Kuvan and Peg-Pal as it seeks to strengthen its focus on its core businesses.
NHS calls in firefighters to reduce winter pressures
The National Health Service is working with firefighters under a new partnership that seeks to address potential health and social issues at an earlier stage, in order to help people live longer, more independent lives and reduce winter pressures on care systems.
UK charity petitions Roche to cut price of Kadcyla
UK charity Breast Cancer Now is petitioning Roche to cut the price of its breast cancer drug Kadcyla – temporarily at least – so that it can remain available to patients in England through the Cancer Drugs Fund.
